Biography
Interests
Mohammad Shoaib Hamrah1*, Mohammad Hassan Hamrah2,6, Mohammad Hussain Hamrah3,6, Ahmad Edris Hamrah6, Mohammad Naim Musammem4, Toba Dahi5 & Mohammad Hashem Hamrah6
1Center for Rural Health, School of Health Sciences, University of Tasmania, Australia
2Faculty of Stomatology, Kunduz University, Kunduz, Afghanistan
3Arya University Faculty of Medicine, Mazar-i-Sharif, Afghanistan
4Faryab Public Health Department, Faryab, Afghanistan
5Faculty of Dentistry, AbantIzzet Baysal University, Bolu, Turkey
6Dr. Mohammad Hashem Hamrah’s Curative Clinic, Andkhoy, Afghanistan
*Correspondence to: Dr. Mohammad Shoaib Hamrah, Center for Rural Health, School of Health Sciences, University of Tasmania, Australia.
Copyright © 2018 Dr. Mohammad Shoaib Hamrah, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Hypertension is a main risk factor for stroke, heart failure, coronary and systemic atherosclerosis, and chronic kidney diseases. The prevalence of hypertension lower in high-income countries compared to in low- and middle-income countries. This article describes recent changes for the classifications, evaluation and treatment of hypertension in adults
Introduction
Hypertension is a major risk factor for stroke, heart failure, coronary and systemic atherosclerosis, and chronic
kidney diseases [1]. Hypertension is responsible for 13% of all deaths, 62% of stroke, and 49% myocardial
infarction [2] According to the 2017 American College of Cardiology-American Heart Association (ACCAHA)
Guideline, Hypertension is defined as systolic blood pressure of ≥130mm Hg or diastolic blood
pressure of ≥ 80mm Hg (hereafter referred to as ≥130/80mm Hg). The 2017 ACC/AHA guideline for
classification of blood pressure is shown in Table 1 [1,3].
The prevalence of hypertension varies in different parts of the world. In 2000, the global prevalence hypertension was 26.4% (26.6% of males and 26.1% of females). The total number of adults with hypertension in 2000 was 972 million; 333 million in developed countries and 639 million developing countries [4]. However, a Systematic Analysis of Population-Based Studies From 90 Countries in 2010 has shown that 31.1% (1.39 billion) of the world’s adults had hypertension; 28.5% in high-income countries and 31.5% in low- and middle-income countries [5].
Pathophysiology
Hypertension is classified as primary (essential) and secondary hypertension. Primary or essential hypertension accounts for 90-95% of adult patients, and the remaining 5-10% of cases are categorized as secondary hypertension [6]. The pathogenesis of essential hypertension is unknown [7]. Primary hypertension is considered as a multifactorial disease arising from the combined interactions action of many genetic, environmental, and behavioral factors [8].
Lifestyle-related factors are linked with an increased risk of hypertension. They include high sodium intake, weight gain, excessive alcohol intake and consumption of some medications or illicit drugs, whereas the secondary causes for hypertension are include renal, renovascular, endocrine and urologic [1]
Management
There are two methods for the treatment of hypertension including non-pharmacologic and pharmacologic
approaches [9]. The treatment of hypertensive patients depends on the presence cardiovascular disease,
diabetes mellitus chronic kidney disease.
According to the 2017 ACC-AHA guideline, the treatment of hypertension decision depends on calculation of 10- year predicted risk of cardiovascular disease estimations (http://tools.acc.org/ASCVD-Risk-Estimator- Plus/#!/calculate/estimate/). Lifestyle modification is recommended for all patients with estimated risk is less than 10% for a period of 3 to 6 months. Both lifestyle modification and anti-hypertensive drugs are recommended for patients with stage 2 hypertension or with a 10-year risk for cardiovascular disease of 10% or higher or with preexisting cardiovascular disease, diabetes mellitus chronic kidney disease. A blood pressure goal of less than 130/80mm Hg is recommended for all hypertensive patients [10].
Non-Pharmacological Therapy
Recommended lifestyle changes for the management of hypertension include restriction of dietary salt,
weight loss if the hypertensive patient is overweight or obese, regular aerobic exercise, moderation of alcohol
intake, smoking cession, and a diet high in fruits, vegetables, and low-fat dairy products. It is believed that
anti-hypertensive effect of lifestyle change can be equivalent to drug monotherapy [10]. Each of these
approaches is likely to decrease systolic blood and diastolic blood pressure by 3-8mm Hg and 1-4mm Hg,
respectively [11].
Pharmacological Therapy
Despite lifestyle changes, if blood pressure is still ≥140/90mm Hg, pharmacologic interventions should be
initiated. Anti-hypertensive drugs include angiotensin converting enzyme (ACE) inhibitors, angiotensin
receptor blockers (ARBs), diuretics, calcium channel blockers and beta-blockers.
Based on ESH/ESC hypertension guideline, grade 1 hypertensive patients with low/moderate cardiovascular risk can start the anti-hypertensive medications with monotherapy as initial treatment [12]. The first-line medication in the treatment of hypertensive patients can be selected from one of the four major drug classes (thiazides, calcium channel blockers, ACE inhibitors and ARBs) [1,13, 14].
Monotherapy
Monotherapy is successfully decrease blood pressure in most patients with mild primary hypertension.
However, monotherapy is not effective in reducing blood pressure than 20/10mm Hg. In this group patients
the combination of wo antihypertensive drugs is recommended [6].
Renin Angiotensin Aldosterone System (RAS) Blockers
RAS blockers have been reduced cardiovascular mortality and incidence of the incidence of end-organ
damage [15]. ACE inhibitors and ARBs are the first-line drugs in the management of diabetic hypertensives
hypertension [16].
Diuretics
Diuretics increase the excretion of renal sodium and water [17]. Diuretics have improved cardiovascular
outcomes and reduce risk of stroke [18]. Thiazide and thiazide-like diuretics have been the gold standard
treatment for primary hypertension [19]. According to the JNC-7, thiazide diuretics are first line drugs to
treat hypertension, either alone or in combination with other classes of anti-hypertensive drugs [20].
Calcium Channel Blockers
Calcium channel blockers are most commonly used antihypertensive drugs. These group of antihypertensive
drugs have potent antihypertensive effects. Calcium channel blockers had efficacy in decreasing cardiovascular
morbidity and mortality among hypertensive patients [21].
Calcium channel blockers are generally categorized into two groups as dihydropyridine and nondihydropyridine groups. as dihydropyridine and non-dihydropyridine groups. Non-dihydropyridine calcium channel blockers are more negatively chronotropic and inotropic compared to the dihydropyridine group. This group of calcium channel blockers are not recommended as first-line drugs in the treatment of hypertension. According to the NICE guidelines (National Institute for Health and Care Excellence), calcium channel blockers can be used as first-line therapy among hypertensive patients older than 55 years [10].
Beta Blockers
The 2013 ESH/ESC guidelines recommended that the use of beta blockers as one of the first-line medication
in the treatment of hypertension [12]. However, the 2014 NICE hypertension guidelines recommended that
beta-blockers should not use as first choice anti-hypertensive drugs. Beta-blockers can be used as additional
therapy to decrease blood pressure and this group of antihypertensive medications are useful in preventing
recurrent coronary artery disease [22].
Alpha Blockers
Alpha blockers are associated with an increase the risk of cardiovascular events Therefore, alpha blockers are
not recommended as the first-line drug for hypertension [19]. These drugs include: Prazosin, Terazosin and
Doxazosin are used only older hypertensive patients with benign prostate hypertrophy [23].
Combination Therapy
A combination therapy is recommended in those patients with a systolic blood pressure >20mmHg and/
or a diastolic blood pressure >10mmHg above the goals and hypertensive patients at high cardiovascular
risk [24]. There are different combinations of antihypertensive drugs. Commonly used combinations of
antihypertensive drugs are ACE inhibitors or ARBs and calcium channel blockers or diuretics which have
fully additive blood pressure reduction [25]. However, combinations calcium channel blocker and diuretics
or beta-blockers and RAS blockers do not have additive blood pressure reduction effects [26].
Conclusion
According to the 2017 ACC-AHA Guideline, hypertension is defined as systolic blood pressure systolic
blood pressure of ≥130mm Hg or diastolic blood pressure of ≥80mm Hg. The treatment of hypertension is
included pharmacologic and non-pharmacologic approaches. Anti-hypertensive drugs include angiotensin
converting enzyme ACE inhibitors, ARBs, diuretics, calcium channel blockers and beta-blockers. A
combination therapy is recommended in those patients with a systolic blood pressure >20mmHg and/or a
diastolic blood pressure >10mmHg above the goals and hypertensive patients at high cardiovascular risk.
Acknowledgement
Our study project was subsidized by the Terumo Foundation for Life Sciences and Arts.
Conflict of Interest
None
Bibliography
Hi!
We're here to answer your questions!
Send us a message via Whatsapp, and we'll reply the moment we're available!